Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Breast Cancer, PI3K, Alpelisib”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Testing effectiveness (Phase 2)Ended earlyNCT03386162
What this trial is testing

SAFIR-PI3K A Phase II Randomized Maintenance Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy in PIK3CA Mutated Advanced Breast Cancer

Who this might be right for
Breast Cancer, PI3K, Alpelisib
UNICANCER 31
Post-approval studies (Phase 4)Study completedNCT05631795
What this trial is testing

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 40
Early research (Phase 1)Study completedNCT02058381
What this trial is testing

A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Pre-menopausal Breast CancerPI3K Pathway Inhibition
Novartis Pharmaceuticals 40
Large-scale testing (Phase 3)Active Not RecruitingNCT04208178
What this trial is testing

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

Who this might be right for
Advanced HER2+Breast Cancer
Novartis Pharmaceuticals 19
Early research (Phase 1)Study completedNCT01791478
What this trial is testing

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerInvasive Ductal Breast Carcinoma+3 more
Vanderbilt-Ingram Cancer Center 46
Testing effectiveness (Phase 2)Study completedNCT02506556
What this trial is testing

Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Peter MacCallum Cancer Centre, Australia 38
Testing effectiveness (Phase 2)Looking for participantsNCT05768139
What this trial is testing

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Who this might be right for
Breast CancerSolid Tumors, Adult
Eli Lilly and Company 880
Early research (Phase 1)Active Not RecruitingNCT05143229
What this trial is testing

Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer

Who this might be right for
Breast Cancer
University of Kansas Medical Center 18
Early research (Phase 1)Study completedNCT01219699
What this trial is testing

BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Who this might be right for
Advanced Solid Tumors With an Alteration of the PIK3CA GeneEstrogen Receptor Positive Breast Cancer
Novartis Pharmaceuticals 221
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07679269
What this trial is testing

Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.

Who this might be right for
PIK3CA-Related Overgrowth Spectrum (PROS)Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)
Novartis Pharmaceuticals 51
Early research (Phase 1)Study completedNCT02051751
What this trial is testing

Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer

Who this might be right for
Neoplasms, Breast Neoplasms, Head and Neck Neoplasms
Novartis Pharmaceuticals 19
Early research (Phase 1)Study completedNCT02077933
What this trial is testing

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Who this might be right for
NeoplasmsBreast NeoplasmsKidney Neoplasms+1 more
Novartis Pharmaceuticals 79
Early research (Phase 1)Active Not RecruitingNCT05508906
What this trial is testing

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Who this might be right for
Metastatic Breast CancerER-positive Breast CancerHER2-negative Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 190
Not applicableLooking for participantsNCT07646171
What this trial is testing

EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)

Who this might be right for
Hormone Receptor Positive Breast Cancer
Tel-Aviv Sourasky Medical Center 19
Large-scale testing (Phase 3)Study completedNCT02437318
What this trial is testing

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 572
Not applicableEnded earlyNCT04967248
What this trial is testing

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Who this might be right for
Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation
Novartis Pharmaceuticals 4
Testing effectiveness (Phase 2)Looking for participantsNCT06993844
What this trial is testing

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorsAdvanced Breast Cancer
Ensem Therapeutics 233